Filtered By:
Specialty: Gastroenterology
Condition: Bleeding

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 54 results found since Jan 2013.

Chemoprevention of Barrett ’s Esophagus and Esophageal Adenocarcinoma
AbstractBarrett ’s esophagus is common in Western countries, but progression to esophageal adenocarcinoma is uncommon. Chemoprevention therefore needs to consider whether benefits outweigh risks given an otherwise healthy population. This will depend on the particular population at risk and the relative safety of a potential preventive agent. Most evidence regarding the potential benefit of chemoprevention of Barrett’s esophagus and prevention of progression to esophageal adenocarcinoma is based on observational studies such as case–control and cohort studies. Given the potential benefits and relatively low risks, pa...
Source: Digestive Diseases and Sciences - June 12, 2018 Category: Gastroenterology Source Type: research

Mo1133 PROSPECTIVE EVALUATION OF 30-DAY BLEEDING AND THROMBOEMBOLIC RISKS IN PATIENTS UNDERGOING COLONOSCOPY WHILE TAKING WARFARIN OR NOVEL ANTICOAGULANTS
With the rising prevalence of ischemic heart disease and atrial fibrillation as well as the expanding indications on the use of anticoagulants, there are increasing number of patients undergoing colonoscopies while on these agents. International societies issued guidelines on the peri-endoscopic management of the anticoagulants but little is known on the actual outcome of these patients, particularly those taking novel anti-coagulants (NOACs). We aim to prospectively evaluate the 30-day morbidities (gastrointestinal bleeding, stroke and cardiovascular complications) and mortalities of patients taking warfarin, NOACs and/or...
Source: Gastrointestinal Endoscopy - May 30, 2018 Category: Gastroenterology Authors: Sze Hang Kevin Liu, Lijia Chen, Sze Kan Leung, Wai K. Leung Tags: Monday abstract Source Type: research

Mo1090 DIRECT-ACTING ORAL ANTICOAGULANT (DOAC) USE IS NOT ASSOCIATED WITH INCREASED RISK OF COMPLICATIONS AFTER POLYPECTOMY
Direct-acting oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran, and edoxaban represent 62% of new anticoagulation prescriptions. Compared to warfarin, DOACs increase the risk of gastrointestinal bleeding but reduce the risk of stroke. Little is known about the risk of complications after polypectomy in patients with active DOAC use. We aimed to determine the risk of complications after polypectomy in this population.
Source: Gastrointestinal Endoscopy - May 30, 2018 Category: Gastroenterology Authors: Jessica X. Yu, Melissa Oliver, Jody Lin, Matthew S. Chang, Allison J. Kwong, Berkeley Limketkai, Roy M. Soetikno, Jayanta Bhattacharya, Tonya R. Kaltenbach Tags: Monday abstract Source Type: research

New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study
ConclusionsGastrointestinal bleeding increased the risk of subsequent mortality during follow‐up of anticoagulated patients, highlighting the importance of prevention. The study developed a new scoring model for acute GI bleeding risk based on five factors (no‐proton pump inhibitor use, chronic kidney disease, chronic obstructive pulmonary disease, history of peptic ulcer disease, and liver cirrhosis), which was superior to the HAS‐BLED score.
Source: Journal of Gastroenterology and Hepatology - December 28, 2017 Category: Gastroenterology Authors: Akira Shimomura, Naoyoshi Nagata, Takuro Shimbo, Toshiyuki Sakurai, Shiori Moriyasu, Hidetaka Okubo, Kazuhiro Watanabe, Chizu Yokoi, Junichi Akiyama, Naomi Uemura Tags: Gastroenterology Source Type: research

Su1162 Gastrointestinal Bleeding With Warfarin, Novel Oral Anticoagulants and Left Atrial Appendage Exclusion Device in Patients With Atrial Fibrillation: Network Meta-Analysis of Randomized Controlled Trials
Novel oral anticoagulants (NOAC) are extensively being used in atrial fibrillation (AF) patients for mitigating stroke risk as an alternative to warfarin. In those patients with higher bleeding risk, left atrial appendage exclusion devices are being used for decreasing stroke risk. We performed a network meta-analysis of all randomized controlled trials (RCT) to compare the relative efficacy of all these agents.
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Avanija Buddam, Arun Kanmanthareddy, Sunil Dacha, Sandeep Mukherjee, Savio Reddymasu Tags: Sunday – ASGE poster Source Type: research

Mo1086 Severity of Gastrointestinal Bleeding in Patients Treated With Direct-Acting Oral Anticoagulants (Doacs)
Direct-acting oral anticoagulants (DOACs), which have recently been approved for stroke prevention in non-valvular atrial fibrillation and treatment of venous thromboembolism, have become increasingly preferred over warfarin given their predictable pharmacodynamics and lack of required monitoring. DOACs have been shown to be associated with an increased frequency of gastrointestinal bleeding (GIB) compared to warfarin, but the severity of GIB in these patients is poorly understood.
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Mark M. Brodie, Tyler Smith, Jill Newman, Don C. Rockey Tags: Monday – ASGE poster Source Type: research

Mo1074 Outcomes of Gastrointestinal Hemorrhage in the Setting of Novel Versus Traditional Antithrombotic Agents
The objective of our study was to compare outcomes among patients presenting with GI bleed that were prescribed novel versus traditional antithrombotic agents.
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Jonathan I. Chang, Elizabeth Dong, Karl Kwok, Bechien U. Wu Tags: Monday – ASGE poster Source Type: research

Risk of Gastrointestinal Bleeding in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants: a Systematic Review and Meta-analysis
Non-vitamin K antagonist oral anticoagulants (NOACs) are convenient and effective in prevention and treatment of venous thromboembolism and prevention of stroke in patients with atrial fibrillation. However, these drugs have been associated with increased risk of gastrointestinal (GI) bleeding. We conducted a systematic review and meta-analysis to determine the risk of GI bleeding in patients receiving these drugs.
Source: Clinical Gastroenterology and Hepatology - April 27, 2017 Category: Gastroenterology Authors: Corey S. Miller, Alastair Dorreen, Myriam Martel, Thao Huynh, Alan N. Barkun Source Type: research

Risk of Gastrointestinal Bleeding in Patients Taking Non –Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-Analysis
Non –vitamin K antagonist oral anticoagulants (novel oral anticoagulants [NOACs]) are convenient and effective in the prevention and treatment of venous thromboembolism and the prevention of stroke in patients with atrial fibrillation. However, these drugs have been associated with an increased risk o f gastrointestinal (GI) bleeding. We conducted a systematic review and meta-analysis to determine the risk of GI bleeding in patients receiving these drugs.
Source: Clinical Gastroenterology and Hepatology - April 27, 2017 Category: Gastroenterology Authors: Corey S. Miller, Alastair Dorreen, Myriam Martel, Thao Huynh, Alan N. Barkun Source Type: research

The impact of minor blood transfusion on the outcome after coronary artery bypass grafting
Conclusion Minor perioperative bleeding and subsequent transfusion of 1–2 RBC units did not affect the risk of early death, but increased the risk of other major adverse events. Minimizing perioperative bleeding and prevention of even low-volume RBC transfusion may improve the outcome after CABG.
Source: Journal of Critical Care - April 23, 2017 Category: Gastroenterology Source Type: research

Safety and feasibility of liver resection with continued antiplatelet therapy using aspirin
ConclusionsLiver resection can be safely performed while continuing aspirin therapy without increasing hemorrhagic morbidity. Our results suggest that interruption of aspirin therapy is unnecessary for patients undergoing liver resection.This article is protected by copyright. All rights reserved.
Source: Journal of Hepato-Biliary-Pancreatic Sciences - April 1, 2017 Category: Gastroenterology Authors: Kazuteru Monden, Hiroshi Sadamori, Masayoshi Hioki, Satoshi Ohno, Hiromi Saneto, Toru Ueki, Kazuhisa Yabushita, Kazumi Ono, Kousaku Sakaguchi, Norihisa Takakura Tags: Original Article Source Type: research

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Abstract Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. However, similar to traditional anticoagulants, NOACs have the side effects of bleeding, including gastrointestinal bleeding (GIB). Results from both randomized clinical trials and observations studies suggest that high-dose dabigatran (150 mg b.i.d), rivaroxaban and high-dose edoxaban (6...
Source: World Journal of Gastroenterology : WJG - March 21, 2017 Category: Gastroenterology Authors: Cheung KS, Leung WK Tags: World J Gastroenterol Source Type: research

Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the “Real World”
The pivotal aim of oral anticoagulation in atrial fibrillation (AF) is prevention of AF-related thromboembolic strokes. The vitamin K antagonists (eg, warfarin) have been the standard of care for many years, reducing both stroke and mortality rates by 64% and 26% respectively, compared with placebo/control.1 Approval and market release of direct oral anticoagulants (DOACs; also referred to as non-vitamin K antagonist oral anticoagulants2), such as dabigatran, rivaroxaban, apixaban, and edoxaban, have changed the landscape of thromboprophylaxis substantially.
Source: Gastroenterology - February 28, 2017 Category: Gastroenterology Authors: Micha ł Mazurek, Gregory Y.H. Lip Tags: Editorial Source Type: research

Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem
Systemic anticoagulation with vitamin K antagonists or direct-acting oral anticoagulants (DOACs) remains the mainstay of therapy to attenuate the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Given more predictable pharmacology, use of fixed-dose regimens, and lack of need for routine drug monitoring, DOACs have enjoyed relatively high uptake and quickly have become integrated into clinical practice.1 Although these agents generally have a favorable index of safety in comparison with warfarin with a lower risk of intracranial hemorrhage, rates of major gastrointestinal (GI) b...
Source: Clinical Gastroenterology and Hepatology - January 13, 2017 Category: Gastroenterology Authors: Muthiah Vaduganathan, Deepak L. Bhatt Tags: Editorial Source Type: research

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation
Gastrointestinal (GI) bleeding in patients receiving anticoagulation agents can be caused by occult malignancies. We investigated the proportions and features of major GI bleeding (MGIB) events related to occult GI cancers in patients receiving anticoagulation therapy.
Source: Clinical Gastroenterology and Hepatology - October 16, 2016 Category: Gastroenterology Authors: Kathryn F. Flack, Jay Desai, Jennifer M. Kolb, Prapti Chatterjee, Lars C. Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart Connolly, Paul Reilly, Martina Brueckmann, John Ilgenfritz, James Aisenberg Source Type: research